{"id":49232,"date":"2026-08-01T01:15:00","date_gmt":"2026-07-31T23:15:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=f1fbeb9b352d637b340b7caf8fbef967"},"modified":"2026-08-01T01:15:00","modified_gmt":"2026-07-31T23:15:00","slug":"icon-announces-results-of-annual-general-meeting","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=49232","title":{"rendered":"ICON Announces Results of Annual General Meeting"},"content":{"rendered":"

DUBLIN--(BUSINESS WIRE)--ICON plc<\/a> (NASDAQ: ICLR),<\/b> a world-leading clinical research organization, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 31, 2026 were duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 26, 2026 and are available on the ICON plc website<\/a>.<\/p><\/a><\/a>

\nThe final results of the voting are as follows:<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\nRESOLUTION NUMBER<\/b><\/p><\/td>

\n\u00a0<\/p><\/td>

\nRESOLUTION<\/b><\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\nTOTAL NUMBER OF VOTES<\/b><\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\nVOTE FOR<\/b><\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\nVOTE AGAINST<\/b><\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\nVOTE WITHHELD<\/b><\/p><\/td>

\n<\/tr>\n

\n1.1<\/b><\/p><\/td>

\n\u00a0<\/p><\/td>

\nTo re-elect Mr. Ciaran Murray<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,388,626<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n66,199,869<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n2,103,468<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n85,289<\/p><\/td>

\n<\/tr>\n

\n1.2<\/b><\/p><\/td>

\n\u00a0<\/p><\/td>

\nTo elect Mr. Barry Balfe<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,388,626<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,109,408<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n193,184<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n86,034<\/p><\/td>

\n<\/tr>\n

\n1.3<\/b><\/p><\/td>

\n\u00a0<\/p><\/td>

\nTo re-elect Mr. R\u00f3n\u00e1n Murphy<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,388,626<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n67,790,940<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n508,110<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n89,576<\/p><\/td>

\n<\/tr>\n

\n1.4<\/b><\/p><\/td>

\n\u00a0<\/p><\/td>

\nTo re-elect Dr. John Climax<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,388,626<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n66,328,049<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n1,971,237<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n89,340<\/p><\/td>

\n<\/tr>\n

\n1.5<\/b><\/p><\/td>

\n\u00a0<\/p><\/td>

\nTo re-elect Ms. Julie O\u2019Neill<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,388,626<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n67,754,504<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n547,823<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n86,299<\/p><\/td>

\n<\/tr>\n

\n1.6<\/b><\/p><\/td>

\n\u00a0<\/p><\/td>

\nTo re-elect Mr. Eugene McCague<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,388,626<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n67,346,798<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n952,212<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n89,616<\/p><\/td>

\n<\/tr>\n

\n1.7<\/b><\/p><\/td>

\n\u00a0<\/p><\/td>

\nTo re-elect Dr. Linda Grais<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,388,626<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n66,748,905<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n1,553,330<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n86,391<\/p><\/td>

\n<\/tr>\n

\n1.8<\/b><\/p><\/td>

\n\u00a0<\/p><\/td>

\nTo re-elect Ms. Anne Whitaker<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,388,626<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,027,624<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n274,579<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n86,423<\/p><\/td>

\n<\/tr>\n

\n1.9<\/b><\/p><\/td>

\n\u00a0<\/p><\/td>

\nTo elect Mr. Kevin Egan<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,388,626<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n67,829,686<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n471,018<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n87,922<\/p><\/td>

\n<\/tr>\n

\n1.10<\/b><\/p><\/td>

\n\u00a0<\/p><\/td>

\nTo elect Mr. Jeff Elliott<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,388,626<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n67,839,921<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n461,026<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n87,679<\/p><\/td>

\n<\/tr>\n

\n2<\/b><\/p><\/td>

\n\u00a0<\/p><\/td>

\nTo review the Company\u2019s affairs and consider the Accounts and Reports<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,388,626<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,354,960<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n22,868<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n10,798<\/p><\/td>

\n<\/tr>\n

\n3<\/b><\/p><\/td>

\n\u00a0<\/p><\/td>

\nTo authorise the fixing of the Auditors' Remuneration<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,388,626<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n67,810,374<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n570,945<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n7,307<\/p><\/td>

\n<\/tr>\n

\n4<\/b><\/p><\/td>

\n\u00a0<\/p><\/td>

\nTo authorise the Company to allot shares<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,388,626<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n66,805,455<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n1,577,886<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n5,285<\/p><\/td>

\n<\/tr>\n

\n5**<\/b><\/p><\/td>

\n\u00a0<\/p><\/td>

\nTo disapply the statutory pre-emption rights<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,388,626<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n65,052,290<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n3,328,252<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n8,084<\/p><\/td>

\n<\/tr>\n

\n6**<\/b><\/p><\/td>

\n\u00a0<\/p><\/td>

\nTo disapply the statutory pre-emption rights for funding capital investment or acquisitions<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,388,626<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n64,417,316<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n3,962,733<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n8,577<\/p><\/td>

\n<\/tr>\n

\n7<\/b><\/p><\/td>

\n\u00a0<\/p><\/td>

\nTo authorise the Company and any subsidiary of the Company to make overseas market purchases of shares<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,388,626<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,276,018<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n40,509<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n72,099<\/p><\/td>

\n<\/tr>\n

\n8**<\/b><\/p><\/td>

\n\u00a0<\/p><\/td>

\nTo authorise the price range at which the Company can reissue shares that it holds as treasury shares<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,388,626<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n68,167,370<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n145,548<\/p><\/td>

\n

\n\u00a0<\/p><\/td>

\n75,708<\/p><\/td>

\n<\/tr>\n<\/table>

\n** Special Resolution. All resolutions are ordinary resolutions unless otherwise stated.<\/p>

\nAbout ICON plc<\/b><\/p>

\nICON plc is a world-leading clinical research organization. Offering deep operational and medical expertise we accelerate innovation, driving emerging therapies forward to improve patient outcomes. From molecule to medicine, we deliver integrated consulting, clinical development, commercialization and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organizations worldwide. With headquarters in Dublin, Ireland, ICON employed approximately 40,200 employees in 99 locations in 55 countries as at June 30, 2026. For further information about ICON, visit: www.iconplc.com<\/a>.<\/p>

\nStatements included herein which are not historical facts are forward-looking statements. Such forward-looking statements are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include, but are not limited to, statements regarding the following: contracted revenue; the repayment of indebtedness; the company's expectations regarding business momentum, market opportunity, demand trends, growth, and commercial performance; and the company's expectations with respect to its long-term value creation and competitive positioning. You can identify many forward-looking statements by words such as \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201ccontinues,\u201d \u201ccould,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cfocused,\u201d \u201cguidance,\u201d \u201cintends,\u201d \u201clook,\u201d \u201cmay,\u201d \u201copportunities,\u201d \u201cplans,\u201d \u201cpositions,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201cseeks,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould\u201d and other similar expressions and the negatives of such expressions. However, not all forward-looking statements contain these words. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. The forward looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, our results could be materially adversely affected. The risks and uncertainties include, but are not limited to, dependence on the pharmaceutical industry and certain clients, the need to regularly win projects and then to execute them efficiently and correctly, the challenges presented by rapid growth, competition and the continuing consolidation of the industry, the impact of market conditions on demand for the company's services, risks related to the company's ability to execute on its commercial strategy and maintain relationships with large pharmaceutical customers, and risks relating to the company's strategic partnerships, the dependence on certain key executives, changes in the regulatory environment, exchange rate fluctuations, inflation and rising labor costs. Please also refer to the section entitled \"Risk Factors\" of our Annual Report on Form 20-F for the year ended December 31, 2025 for a discussion of some of the principal risks that could adversely affect our business, operations and financial results. The company\u2019s forward-looking statements speak only as of the date of this document or as of the date they are made, and the company undertakes no obligation to update its forward-looking statements.<\/p>

\nICON\/ICLR-F<\/p> Contacts<\/b>

\nInvestor Relations +1 888 381 7923\nNigel Clerkin Chief Financial Officer +353 1 291 2000\nKate Haven Vice President Investor Relations +1 888 381 7923\nAll at ICON<\/p>","protected":false},"excerpt":{"rendered":"

DUBLIN–(BUSINESS WIRE)–ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 31, 2026 were duly passed by shareholders. These reso…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-49232","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/49232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49232"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/49232\/revisions"}],"predecessor-version":[{"id":49233,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/49232\/revisions\/49233"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}